Literature DB >> 16785997

Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential.

J Wang1, Z-L Ou, Y-F Hou, J-M Luo, Z-Z Shen, J Ding, Z-M Shao.   

Abstract

In addition to the role in regulating leukocyte trafficking, chemokines recently have been shown to be involved in cancer growth and metastasis. Chemokine network in tumor neovascularity may be regulated by decoy receptors. Duffy antigen receptor for chemokines (DARC) is a specific decoy receptor binding with the angiogenic CC and CXC chemokines. To investigate the effects of DARC on the tumorigenesis and the metastasis potential of human breast cancer cells, human DARC cDNA was reintroduced into the MDA-MB-231 and MDA-MB-435HM cells which have a high capability of spontaneous pulmonary metastasis. We demonstrated that DARC overexpression induced inhibition of tumorigenesis and/or metastasis through interfering with the tumor angiogenesis in vivo. This inhibition is associated with decreasing CCL2 protein levels, and MVD and MMP-9 expression in xenograft tumors. In human breast cancer samples, we also demonstrated that low expression of the DARC protein is significantly associated with estrogen receptor (ER) status, MVD, lymph node metastasis, distant metastasis and poor survival. Our results suggest for the first time that DARC is a negative regulator of growth in breast cancer, mainly by sequestration of angiogenic chemokines and subsequent inhibition of tumor neovascularity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785997     DOI: 10.1038/sj.onc.1209703

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  53 in total

1.  A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines.

Authors:  Dorota Smolarek; Claude Hattab; Gholamreza Hassanzadeh-Ghassabeh; Sylvie Cochet; Carlos Gutiérrez; Alexandre G de Brevern; Rachanee Udomsangpetch; Julien Picot; Magdalena Grodecka; Kazimiera Wasniowska; Serge Muyldermans; Yves Colin; Caroline Le Van Kim; Marcin Czerwinski; Olivier Bertrand
Journal:  Cell Mol Life Sci       Date:  2010-05-11       Impact factor: 9.261

Review 2.  Chemokines as mediators of angiogenesis.

Authors:  Borna Mehrad; Michael P Keane; Robert M Strieter
Journal:  Thromb Haemost       Date:  2007-05       Impact factor: 5.249

3.  Shedding light on DARC: the role of the Duffy antigen/receptor for chemokines in inflammation, infection and malignancy.

Authors:  K Horne; Ian J Woolley
Journal:  Inflamm Res       Date:  2009-03-17       Impact factor: 4.575

Review 4.  In silico studies on DARC.

Authors:  Alexandre G de Brevern; Ludovic Autin; Yves Colin; Olivier Bertrand; Catherine Etchebest
Journal:  Infect Disord Drug Targets       Date:  2009-06

5.  Differences in Baseline Characteristics and White Blood Cell Ratios Between Racial Groups in Patients with Pancreatic Adenocarcinoma.

Authors:  Benjamin E Ueberroth; Adnan Khan; Kevin J Zhang; Philip A Philip
Journal:  J Gastrointest Cancer       Date:  2021-03

6.  Absence of multiple atypical chemokine binders (ACBs) and the presence of VEGF and MMP-9 predict axillary lymph node metastasis in early breast carcinomas.

Authors:  Xiao-Hua Zeng; Zhou-Luo Ou; Ke-Da Yu; Lan-Yun Feng; Wen-Jing Yin; Jing Li; Zhen-Zhou Shen; Zhi-Min Shao
Journal:  Med Oncol       Date:  2014-08-06       Impact factor: 3.064

Review 7.  Chemokines: novel targets for breast cancer metastasis.

Authors:  Simi Ali; Gwendal Lazennec
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

Review 8.  Monocyte chemoattractant protein-1 (MCP-1): an overview.

Authors:  Satish L Deshmane; Sergey Kremlev; Shohreh Amini; Bassel E Sawaya
Journal:  J Interferon Cytokine Res       Date:  2009-06       Impact factor: 2.607

9.  Human Sulfatase 2 inhibits in vivo tumor growth of MDA-MB-231 human breast cancer xenografts.

Authors:  Sarah M Peterson; Andrea Iskenderian; Lynette Cook; Alla Romashko; Kristen Tobin; Michael Jones; Angela Norton; Alicia Gómez-Yafal; Michael W Heartlein; Michael F Concino; Lucy Liaw; Paolo G V Martini
Journal:  BMC Cancer       Date:  2010-08-13       Impact factor: 4.430

10.  DARC on RBC limits lung injury by balancing compartmental distribution of CXC chemokines.

Authors:  Jörg Reutershan; Brian Harry; Daniel Chang; Gregory J Bagby; Klaus Ley
Journal:  Eur J Immunol       Date:  2009-06       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.